Post

India’s Serum Institute Invests in IntegriMedical of Indiana

India’s Serum Institute Invests in IntegriMedical of Indiana

Pune-based Serum Institute of India (SII) announced a strategic investment in IntegriMedical, based in Bainbridge, IN. where SII will acquire a 20% stake in the company. This partnership aims to advance IntegriMedical’s Needle-Free Injection System (N-FIS) technology, aligning with SII’s vision of ‘Health for All’ and IntegriMedical’s mission to ‘Transform Healthcare Globally.”

N-FIS utilizes a high-velocity jet stream powered by mechanical force to effectively and consistently administer biologics and liquid medications without needles. This needle-free drug delivery solution seeks to alleviate pain during administration, providing needle-phobic patients with a more pleasant and stress-free experience while enhancing medication efficacy through needle-free dispersion.

Adar Poonawalla, CEO of SII. expressed excitement about IntegriMedical’s N-FIS, envisioning its potential to revolutionize vaccine administration by offering a needle-free solution, making the process more comfortable for patients and healthcare professionals.

Sarvesh Mutha, managing director of IntegriMedical, welcomed SII as a strategic partner, stating that the investment validates the transformative potential of their technology in drug delivery. He emphasized that SII’s expertise in vaccine manufacturing and global distribution will be invaluable in making the technology more widely accessible to patients worldwide.

IntegriMedical’s N-FIS has already received regulatory approvals from CDSCO, CE, MDSAP, and is ISO 13485 certified. Additionally, the technology is patented in the United States.

Ankur Naik, managing director at IntegriMedical, has been instrumental in the development and clinical trials of the N-FIS, demonstrating its effectiveness in reducing pain and eliminating needle-phobia in patients.

Together, the two companies aim to expand access to care and improve efficiencies in the global healthcare industry.

Initially, N-FIS will be available in the Indian private market, offering patients and healthcare providers an alternative to traditional needle-based injections.

Last updated: December 26th, 2025

Share

About Amritt

Who We Are

Amritt Inc. is a management advisory service facilitating trade between the world and India. Amritt was founded in 2003 and since then it has provided guidance to western companies in entering new markets, global strategy execution, finding and managing supplier partners, and establishing overseas offices. Our primary focus is in helping American, Canadian and European executives to attain success in India.

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Blog
Page
Dictionary
Comparisons
Capabilities
India Business Guide
Services
Private
Speaking
Insights
White Papers
News
Newsletters
Clients
Case Studies
Companies In India
Webinars
Presentations
Industries